Trinucleotide repeat disorders

Annual Review of Neuroscience

Volumn 30, Issue , 2007, Pages 575-621

  Orr, Harry T ^a   Zoghbi, Huda Y ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Ataxia; Ataxin; Fragile X syndrome; Frataxin; Huntington disease; Mental retardation; Myotonic dystrophy; Polyglutamine; Spinal bulbar muscular atrophy; Unstable repeats

Indexed keywords

ATAXIA; CELL ENERGY; CELL SURVIVAL; CYTOLOGY; GENE MUTATION; GENETIC COUNSELING; HUMAN; HUNTINGTON CHOREA; MENTAL DEFICIENCY; MUSCULAR DYSTROPHY; NERVE CELL PLASTICITY; NEUROBIOLOGY; NEUROLOGIC DISEASE; NEUROPATHOLOGY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CONFORMATION; REVIEW; RNA PROCESSING; TRINUCLEOTIDE REPEAT;

ANIMALS; BRAIN; CEREBELLAR ATAXIA; FRAGILE X SYNDROME; GENETIC PREDISPOSITION TO DISEASE; HEREDODEGENERATIVE DISORDERS, NERVOUS SYSTEM; HUMANS; HUNTINGTON DISEASE; MUTATION; PEPTIDES; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 34547692622     PISSN: 0147006X     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.neuro.29.051605.113042     Document Type: Review

References (307)

1. Aguiar J, Fernandez J, Aguilar A, Mendoza Y, Vazquez M, et al. 2006. Ubiquitous expression of human SCA2 gene under the regulation of the SCA2 self promoter cause specific Purkinje cell degeneration in transgenic mice. Neurosci. Lett. 392:202-6
2. Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, Holden JJ, Yang KT, et al. 1999. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in fragile X study - preliminary data. Am. J. Med. Genet. 83:322-25
3. Anderson PR, Kirby K, Hilliker AJ, Phillips JP. 2005. RNAi-mediated suppression of the mitochondrial iron chaperone, frataxin, in Drosophila. Hum. Mol. Genet. 14:3397-405
4. Andrade MA, Bork P. 1995. HEAT repeats in the Huntington's disease protein. Nat. Genet. 11:115-16
5. Arbizu T, Santamaria J, Gomez JM, Quilez A, Serra JP. 1983. A family with adult spinal and bulbar muscular atrophy, X-linked inheritance and associated testicular failure. J. Neurol. Sci. 59:371-82
6. Artuch R, Aracil A, Mas A, Colome C, Rissech M, et al. 2002. Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics 33:190-93
7. Babcock M, de Silva D, Oaks R, Davis-Kaplan S, Jiralerspong S, et al. 1997. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 276:1709-12
8. Bakker CE, de Diego Otero Y, Bontekoe C, Raghoe P, Luteijn T, et al. 2000. Immunocytochemical and biochemical characterization of FMRP, FXR1P, and FXR2P in the mouse. Exp. Cell Res. 258:162-70
9. Bakker CE, Verheij C, Willemsen R, Vanderhelm R, Oerlemans F, et al. 1994. Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 78:23-33
10. Becher MW, Rubinsztein DC, Leggo J, Wagster MV, Stine OC, et al. 1997. Dentatorubral and pallidoluysian atrophy (DRPLA). Clinical and neuropathological findings in genetically confirmed North American and European pedigrees. Mov. Disord. 12:519-30
11. Bence NF, Sampat RM, Kopito RR. 2001. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292:1552-55
12. Bhide PG, Day M, Sapp E, Schwarz C, Sheth A, et al. 1996. Expression of normal and mutant huntingtin in the developing brain. J. Neurosci. 16:5523-35
13. Black DL. 2003. Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 72:291-336
14. Block-Galarza J, Chase KO, Sapp E, Vaughn KT, Vallee RB, et al. 1997. Fast transport and retrograde movement of huntingtin and HAP 1 in axons. NeuroReport 8:2247-51
15. Bowman AB, Lam CY, Jafar-Nejad P, Chen HK, Richman R, et al. 2007. Duplication of Ataxin-1B/Boat suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ATAXIN-1 into its native complexes. Nat. Genet. 39:373-79
16. Bowman AB, Yoo SY, Dantuma NP, Zoghbi HY. 2005. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum. Mol. Genet. 14:679-91
17. Brais B, Bouchard JP, Xie YG, Rochefort DL, Chretien N, et al. 1998. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat. Genet. 18:164-67. Erratum. 1998. Nat. Genet. 19(4):404
18. Brennan FX, Albeck DS, Paylor R. 2006. Fmr1 knockout mice are impaired in a leverpress escape/avoidance task. Genes Brain Behav. 5:467-71
19. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, et al. 1992. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 68:799-808
20. Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, et al. 2001. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107:477-87
21. Bulteau AL, O'Neill HA, Kennedy MC, Ikeda-Saito M, Isaya G, Szweda LI. 2004. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 305:242-45
22. Burnett B, Li FS, Pittman RN. 2003. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum. Mol. Genet. 12:3195-205
23. Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, et al. 1997. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet. 6:1771-80
24. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, et al. 1996. Friedreich's ataxia autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271:1423-27
25. Cassandro E, Mosca F, Sequino L, De Falco FA, Campanella G. 1986. Otoneurological findings in Friedreich's ataxia and other inherited neuropathies. Audiology 25:84-91
26. Ceman S, Brown V, Warren ST. 1999. Isolation of an FMRP-associated messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-related proteins as components of the complex. Mol. Cell. Biol. 19:7925-32
27. Chai Y, Berke SS, Cohen RE, Paulson HL. 2004. Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J. Biol. Chem. 279:3605-11
28. Chantrel-Groussard K, Geromel V, Puccio H, Koenig M, Munnich A, et al. 2001. Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum. Mol. Genet. 10:2061-67
29. Charlet BN, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA. 2002. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol. Cell. 10:45-53
30. Chevalier-Larsen ES, O'Brien CJ, Wang H, Jenkins SC, Holder L, et al. 2004. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J. Neurosci. 24:4778-86
31. Child JS, Perloff JK, Bach PB, Wolfe AD, Perlman S, Kark RA. 1986. Cardiac involvement in Friedreich's ataxia: a clinical study of 75 patients. J. Am. Coll. Cardiol. 7:1370-78
32. Chiurazzi P, Pomponi MG, Willemsen R, Oostra BA, Neri G. 1998. In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum. Mol. Genet. 7:109-13
33. Cho DH, Tapscott SJ. 2006. Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim. Biophys. Acta 1772:195-204
34. Clabough EB, Zeitlin SO. 2006. Deletion of the triplet repeat encoding polyglutamine within the mouse Huntington's disease gene results in subtle behavioral/motor phenotypes in vivo and elevated levels of ATP with cellular senescence in vitro. Hum. Mol. Genet. 15:607-23
35. Coffee B, Zhang F, Warren ST, Reines D. 1999. Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat. Genet. 22:98-101. Erratum. 1999. Nat. Genet. 22(2):209
36. Cossee M, Puccio H, Gansmuller A, Koutnikova H, Dierich A, et al. 2000. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum. Mol. Genet. 9:1219-26
37. Cossee M, Schmitt M, Campuzano V, Reutenauer L, Moutou C, et al. 1997. Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc. Natl. Acad. Sci. USA 94:7452-57
38. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. 2006. Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127:59-69
39. Cummings CJ, Reinstein E, Sun Y, Antalffy B, Jiang Y, et al. 1999. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24:879-92
40. Custer SK, Garden GA, Gill N, Rueb U, Libby RT, et al. 2006. Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat. Neurosci. 9:1302-11
41. Darnell JC, Fraser CE, Mostovetsky O, Stefani G, Jones TA, et al. 2005. Kissing complex RNAs mediate interaction between the Fragile-X mental retardation protein KH2 domain and brain polyribosomes. Genes Dev. 19:903-18
42. Darnell JC, Jensen KB, Jin P, Brown V, Warren ST, Darnell RB. 2001. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell 107:489-99
43. David G, Abbas N, Stevanin G, Durr A, Yvert G, et al. 1997. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat. Genet. 17:65-70
44. Davis BM, McCurrach ME, Taneja KL, Singer RH, Housman DE. 1997. Expansion of a CUG trinucleotide repeat in the 3′ untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proc. Natl. Acad. Sci. USA 94:7388-93
45. de Haro M, Al-Ramahi I, De Gouyon B, Ukani L, Rosa A, et al. 2006. MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum. Mol. Genet. 15:2138-45
46. De Pablos C, Berciano J, Calleja J. 1991. Brain-stem auditory evoked potentials and blink reflex in Friedreich's ataxia. J. Neurol. 238:212-16
47. D'Hooge R, Nagels G, Franck F, Bakker CE, Reyniers E, et al. 1997. Mildly impaired water maze performance in male Fmr1 knockout mice. Neuroscience 76:367-76
48. DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, et al. 1995. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14:1075-81
49. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, et al. 1997. Aggregation of Huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-93
50. Di Prospero NA, Fischbeck KH. 2005. Therapeutics development for triplet repeat expansion diseases. Nat. Rev. Genet. 6:756-65
51. Dobkin C, Rabe A, Dumas R, El Idrissi A, Haubenstock H, Brown WT. 2000. Fmr1 knockout mouse has a distinctive strain-specific learning impairment. Neuroscience 100:423-29
52. Donaldson KM, Li W, Ching KA, Batalov S, Tsai CC, Joazeiro CA. 2003. Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates. Proc. Natl. Acad. Sci. USA 100:8892-97
53. Dragatsis I, Levine MS, Zeitlin S. 2000. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 26:300-6
54. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, et al. 2002. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296:2238-43
55. Dunn CD, Jensen RE. 2003. Suppression of a defect in mitochondrial protein import identifies cytosolic proteins required for viability of yeast cells lacking mitochondrial DNA. Genetics 165:35-45
56. Dürr A, Cossee M, Agid Y, Campuzano V, Mignard C, et al. 1996. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N. Engl. J. Med. 335:1169-75
57. Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT, et al. 1995. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269:407-10
58. Enevoldson TP, Sanders MD, Harding AE. 1994. Autosomal dominant cerebellar ataxia with pigmentary macular dystrophy. A clinical and genetic study of eight families. Brain 117(Pt. 3):445-60
59. Engelender S, Sharp AH, Colomer V, Tokito MK, Lanahan A, et al. 1997. Huntingtin-associated protein 1 (HAP1) interacts with the p150Glued subunit of dynactin. Hum. Mol. Genet. 6:2205-12
60. Fantus IG, Janjua N, Senni H, Andermann E. 1991. Glucose intolerance in first-degree rela tives of patients with Friedreich's ataxia is associated with insulin resistance: evidence for a closely linked inherited trait. Metabolism 40:788-93
61. Faustino NA, Cooper TA. 2003. Pre-mRNA splicing and human disease. Genes Dev. 17:419-37
62. Feng Y, Absher D, Eberhart DE, Brown V, Malter HE, Warren ST. 1997. FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association. Mol. Cell. 1:109-18
63. Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, et al. 2000. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408:101-6
64. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, et al. 2003. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23:9418-27
65. Filla A, De Michele G, Cavalcanti F, Pianese L, Monticelli A, et al. 1996. The relationship between trinucleotide (GAA) repeat length and clinic features in Fredrich ataxia. Am. J. Hum. Genet. 59:554-60
66. Foury F. 1999. Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain. FEBS Lett. 456:281-84
67. Foury F, Cazzalini O. 1997. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett. 411:373-77
68. Friedreich N. 1863. Über degenerative Atrophie der spinalen Hinterstrange. Virchows Arch. A 26:433-59
69. Fu YH, Kuhl DPA, Pizutti A, Pieretti M, Sutcliffe JS, et al. 1991. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67:1047-58
70. Fu YH, Pizutti A, Fenwick RG, King JJ, Rajnarayan S, et al. 1992. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 255:1256-59
71. Fujigasaki H, Uchihara T, Koyano S, Iwabuchi K, Yagishita S, et al. 2000. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains. Exp. Neurol. 165:248-56
72. Garden GA, Libby RT, Fu YH, Kinoshita Y, Huang J, et al. 2002. Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous Purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. J. Neurosci. 22:4897-905
73. Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, et al. 2005. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 280:556-63
74. Gatchel JR, Zoghbi HY. 2005. Diseases of unstable repeat expansion: mechanisms and common principles. Nat. Rev. Genet. 6:743-55
75. Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, et al. 2004. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127-38
76. Gecz J, Bielby S, Sutherland GR, Mulley JC. 1997. Gene structure and subcellular localization of FMR2, a member of a new family of putative transcription activators. Genomics 44:201-13
77. Gecz J, Gedeon AK, Sutherland GR, Mulley JC. 1996. Identification of the gene FMR2, associated with FRAXE mental retardation. Nat. Genet. 13:105-8
78. Gill G, Tjian R. 1992. Eukaryotic coactivators associated with the TATA box binding protein. Curr. Opin. Genet. Dev. 2:236-42
79. Goehler H, Lalowski M, Stelzl U, Waelter S, Stroedicke M, et al. 2004. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol. Cell. 15:853-65
80. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, et al. 2006. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125:1179-91
81. Greco CM, Berman RF, Martin RM, Tassone F, Schwartz PH, et al. 2006. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 129:243-55
82. Greco CM, Hagerman RJ, Tassone F, Chudley AE, Del Bigio MR, et al. 2002. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 125:1760-71
83. Greenfield JG. 1954. The Spino-Cerebellar Degenerations. Springfield, IL: Charles C. Thomas
84. Gu Y, McIlwain KL, Weeber EJ, Yamagata T, Xu B, et al. 2002. Impaired conditioned fear. and enhanced long-term potentiation in Fmr2 knock-out mice. J. Neurosci. 22:2753-63
85. Gu Y, Shen Y, Gibbs RA, Nelson DL. 1996. Identification of FMR2, a novel gene associated with the FRAXE CCG repeat and CpG. Nat. Genet. 13:109-13
86. Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, et al. 2003. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40:25-40
87. Gutekunst CA, Levey AI, Heilman CJ, Whaley WL, Yi H, et al. 1995. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc. Natl. Acad. Sci. USA 92:8710-14
88. Hagerman PJ, Hagerman RJ. 2004a. Fragile X-associated tremor/ataxia syndrome (FXTAS). Ment. Retard. Dev. Disabil. Res. Rev. 10:25-30
89. Hagerman PJ, Hagerman RJ. 2004b. The fragile-X premutation: a maturing perspective. Am. J. Hum. Genet. 74:805-16
90. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, et al. 2001. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 57:127-30
91. Hagerman RJ, Van Housen K, Smith AC, McGavran L. 1984. Consideration of connective tissue dysfunction in the fragile X syndrome. Am. J. Med. Genet. 17:111-21
92. Hamilton BA, Frankel WN, Kerrebrock AW, Hawkins TL, FitzHugh W, et al. 1996. Disruption of the nuclear hormone receptor RORα in staggerer mice. Nature 379:736-39
93. Harjes P, Wanker EE. 2003. The hunt for huntingtin function: Interaction partners tell many different stories. Trends Biochem. Sci. 28:425-33
94. Harrison CJ, Jack EM, Allen TD, Harris R. 1983. The fragile X: a scanning electron microscope study. J. Med. Genet. 20:280-85
95. Hart RP, Henry GK, Kwentus JA, Leshner RT. 1986. Information processing speed of children with Friedreich's ataxia. Dev. Med. Child Neurol. 28:310-13
96. Hausse AO, Aggoun Y, Bonnet D, Sidi D, Munnich A, et al. 2002. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 87:346-49
97. He Y, Zu T, Benzow KA, Orr HT, Clark HB, Koob MD. 2006. Targeted deletion of a single Sca8 ataxia locus allele in mice causes abnormal gait, progressive loss of motor coordination, and Purkinje cell dendritic deficits. J. Neurosci. 26:9975-82
98. Helmlinger D, Hardy S, Abou-Sleymane G, Eberlin A, Bowman AB, et al. 2006. Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLOS Biol. 4:e67
99. Helmlinger D, Hardy S, Sasorith S, Klein F, Robert F, et al. 2004. Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum. Mol. Genet. 13:1257-65
100. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. 2006. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol. 2:551-58
101. Ho TH, Bundman D, Armstrong DL, Cooper TA. 2005a. Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Hum. Mol. Genet. 14:1539-47
102. Ho TH, Savkur RS, Poulos MG, Mancini MA, Swanson MS, Cooper TA. 2005b. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. J. Cell Sci. 118:2923-33
103. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, et al. 2003. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA 100:2041-46
104. Holmes SE, O'Hearn E, Rosenblatt A, Callahan C, Hwang HS, et al. 2001a. A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2. Nat. Genet. 29:377-78
105. Holmes SE, O'Hearn E, Ross CA, Margolis RL. 2001b. SCA12: an unusual mutation leads to an unusual spinocerebellar ataxia. Brain Res. Bull. 56:397-403
106. Holmes SE, O'Hearn EE, McInnis MG, Gorelick-Feldman DA, Kleiderlein JJ, et al. 1999. Expansion of a novel CAG trinucleotide repeat in the 5′ region of PPP2R2B is associated with SCA12. Nat. Genet. 23:391-92
107. Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E. 2006. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 51:441-54
108. Huber KM, Gallagher SM, Warren ST, Bear MF. 2002. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. USA 99:7746-50
109. Hughes RE. 2002. Polyglutamine disease: acetyltransferases awry. Curr. Biol. 12:R141-43
110. Huynh DP, Del Bigio MR, Ho DH, Pulst SM. 1999. Expression of ataxin-2 in brains from normal individuals and patients with Alzheimer's disease and spinocerebellar ataxia 2. Ann. Neurol. 45:232-41
111. Huynh DP, Figueroa K, Hoang N, Pulst SM. 2000. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat. Genet. 26:44-50
112. Huynh DP, Yang HT, Vakharia H, Nguyen D, Pulst SM. 2003. Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. Hum. Mol. Genet. 12:1485-96
113. Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya S, Kakizuka A. 1996. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat. Genet. 13:196-202
114. Irwin S, Vandelft M, Pinchev D, Howell JL, Graczyk J, et al. 2005. RNA association and nucleocytoplasmic shuttling by ataxin-1. J. Cell Sci. 118:233-42
115. Irwin SA, Idupulapati M, Gilbert ME, Harris JB, Chakravarti AB, et al. 2002. Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice. Am. J. Med. Genet. 111:140-46
116. Irwin SA, Patel B, Idupulapati M, Harris JB, Crisostomo RA, et al. 2001. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am. J. Med. Genet. 98:161-67
117. Iwahashi CK, Yasui DH, An HJ, Greco CM, Tassone F, et al. 2006. Protein composition of the intranuclear inclusions of FXTAS. Brain 129:256-71
118. Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA. 2007. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol. 6:45-55
119. Jacquemont S, Hagerman RJ, Leehey M, Grigsby J, Zhang L, et al. 2003. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am. J. Hum. Genet. 72:869-78
120. James TN, Cobbs BW, Coghlan HC, McCoy WC, Fisch C. 1987. Coronary disease, cardioneuropathy, and conduction system abnormalities in the cardiomyopathy of Friedreich's ataxia. Br. Heart J. 57:446-57
121. Jansen G, Groenen PJ, Bachner D, Jap PH, Coerwinkel M, et al. 1996. Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice. Nat. Genet. 13:316-24
122. Jauslin ML, Meier T, Smith RA, Murphy MP. 2003. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 17:1972-74
123. Jin P, Zarnescu DC, Ceman S, Nakamoto M, Mowrey J, et al. 2004. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat. Neurosci. 7:113-17
124. Jin P, Zarnescu DC, Zhang F, Pearson CE, Lucchesi JC, et al. 2003. RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila. Neuron 39:739-47
125. Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, et al. 2003. A muscleblind knockout model for myotonic dystrophy. Science 302:1978-80
126. Karthikeyan G, Santos JH, Graziewicz MA, Copeland WC, Isaya G, et al. 2003. Reduction in frataxin causes progressive accumulation of mitochondrial damage. Hum. Mol. Genet. 12:3331-42
127. Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, et al. 2003. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat. Med. 9:768-73
128. Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, et al. 2002. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35:843-54
129. Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, et al. 1994. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat. Genet. 8:221-27
130. Kazantsev A, Preisinger E, Dranovsky A, Goldgaber D, Housman D. 1999. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl. Acad. Sci. USA 96:11404-9
131. Kenneson A, Zhang F, Hagedorn CH, Warren ST. 2001. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum. Mol. Genet. 10:1449-54
132. Kiehl TR, Nechiporuk A, Figueroa KP, Keating MT, Huynh DP, Pulst SM. 2006. Generation and characterization of Sca2 (ataxin-2) knockout mice. Biochem. Biophys. Res. Commun. 339:17-24
133. Kim DH, Langlois MA, Lee KB, Riggs AD, Puymirat J, Rossi JJ. 2005. HnRNP H inhibits nuclear export of mRNA containing expanded CUG repeats and a distal branch point sequence. Nucleic Acids Res. 33:3866-74
134. Klement IA, Skinner PJ, Kaytor MD, Yi H, Hersch SM, et al. 1998. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95:41-53
135. Klesert TR, Cho DH, Clark JI, Maylie J, Adelman J, et al. 2000. Mice deficient in Six5 develop cataracts: implications for myotonic dystrophy. Nat. Genet. 25:105-9
136. Knight SJL, Flannery AV, Hirst MC, Campbell L, Christodoulou Z, et al. 1993. Trinucleotide repeat amplification and hypermethylation of a CpG island in FRAXE mental retardation. Cell 74:127-34
137. Koch MC, Grimm T, Harley HG, Harper PS. 1991. Genetic risks for children of women with myotonic dystrophy. Am. J. Hum. Genet. 48:1084-91
138. Koekkoek SK, Yamaguchi K, Milojkovic BA, Dortland BR, Ruigrok TJ, et al. 2005. Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in fragile X syndrome. Neuron 47:339-52
139. Koide R, Ikeuchi T, Onodera O, Tanaka H, Igarashi S, et al. 1994. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat. Genet. 6:9-13
140. Koide R, Kobayashi S, Shimohata T, Ikeuchi T, Maruyama M, et al. 1999. A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Hum. Mol. Genet. 8:2047-53
141. Koob MD, Moseley ML, Schut LJ, Benzow KA, Bird TD, et al. 1999. An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8). Nat. Genet. 21:379-84
142. 2+ channel α1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity. Hum. Mol. Genet. 15:1587-99
143. Kozlov G, Trempe JF, Khaleghpour K, Kahvejian A, Ekiel I, Gehring K. 2001. Structure and function of the C-terminal PABC domain of human poly(A)-binding protein. Proc. Natl. Acad. Sci. USA 98:4409-13
144. Ladd AN, Stenberg MG, Swanson MS, Cooper TA. 2005. Dynamic balance between activation and repression regulates pre-mRNA alternative splicing during heart development. Dev. Dyn. 233:783-93
145. Laggerbauer B, Ostareck D, Keidel EM, Ostareck-Lederer A, Fischer U. 2001. Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum. Mol. Genet. 10:329-38
146. Lam YC, Bowman AB, Jafar-Nejad P, Lim J, Richman R, et al. 2006. ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 127:1335-47
147. Lamarche JB, Shapcott D, Côté M, Lemieux B. 1993. Cardiac iron deposits in Friedreich's ataxia. In Handbook of Cerebellar Diseases, ed. R Lechtenberg, pp. 453-58. New York: Marcel Dekker. 1st ed.
148. Langlois MA, Boniface C, Wang G, Alluin J, Salvaterra PM, et al. 2005. Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J. Biol. Chem. 280:16949-54
149. Langlois MA, Lee NS, Rossi JJ, Puymirat J. 2003. Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. Mol. Ther. 7:670-80
150. La Spada AR, Fu YH, Sopher BL, Libby RT, Wang X, et al. 2001. Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron 31:913-27
151. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck H. 1991. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77-79
152. Lee A, Li WJ, Xu KY, Bogert BA, Su K, Gao FB. 2003. Control of dendritic development by the Drosophila fragile X-related gene involves the small GTPase Rac1. Development 130:5543-52
153. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, et al. 2005. PGC-1α deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLOS Biol. 3:e101
154. Lesuisse E, Santos R, Matzanke BF, Knight SA, Camadro JM, Dancis A. 2003. Iron use for haeme synthesis is under control of the yeast frataxin homologue (Yfh1). Hum. Mol. Genet. 12:879-89
155. Li FS, Macfarlan T, Pittman RN, Chakravarti D. 2002. Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J. Biol. Chem. 277:45004-12
156. Li SH, Cheng AL, Zhou H, Lam S, Rao M, et al. 2002. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell. Biol. 22:1277-87
157. Glued. J. Neurosci. 18:1261-69
158. Li SH, Schilling G, Young WSI, Li XJ, Margolis RL, et al. 1993. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 11:985-93
159. Li Z, Zhang Y, Ku L, Wilkinson KD, Warren ST, Feng Y. 2001. The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res. 29:2276-83
160. Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, et al. 2004. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1α null mice. Cell 119:121-35
161. Lin MT, Beal MF. 2006. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787-95
162. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, et al. 2001. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293:864-67
163. Lubs HA. 1969. A marker X chromosome. Am. J. Hum. Genet. 21:231-44
164. MacDonald ME. 2003. Huntingtin: alive and well and working in middle management. Sci. STKE 2003:pe48
165. Machuca-Tzili L, Brook D, Hilton-Jones D. 2005. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve 32:1-18
166. Machuca-Tzili L, Thorpe H, Robinson TE, Sewry C, Brook JD. 2006. Flies deficient in Muscleblind protein model features of myotonic dystrophy with altered splice forms of Z-band associated transcripts. Hum. Genet. 120:487-99
167. Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, et al. 1992. Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science 255:1253-55
168. Mahadevan MS, Yadava RS, Yu Q, Balijepalli S, Frenzel-McCardell CD, et al. 2006. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat. Genet. 38:1066-70
169. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. 1996. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506
170. Mangus DA, Amrani N, Jacobson A. 1998. Pbp1p, a factor interacting with Saccharomyces cerevisiae poly(A)-binding protein, regulates polyadenylation. Mol. Cell Biol. 18:7383-96
171. Mankodi A, Logigian E, Callahan L, McClain C, White R, et al. 2000. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289:1769-73
172. Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, et al. 2002. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol. Cell. 10:35-44
173. Mao Y, Senic-Matuglia F, Di Fiore PP, Polo S, Hodsdon ME, De Camilli P. 2005. Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain. Proc. Natl. Acad. Sci. USA 102:12700-5
174. Martin JP, Bell J. 1943. A pedigree of mental defect showing sex-linkage. J. Neurol. Psychiatry 6:154-57
175. Matsuura T, Yamagata T, Burgess DL, Rasmussen A, Grewal RP, et al. 2000. Large expansion of ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat. Genet. 26:191-94
176. McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, et al. 2005. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45:753-64
177. McMahon SJ, Pray-Grant MG, Schieltz D, Yates JR, Grant PA. 2005. Polyglutamine-expanded spinocerebellar ataxia-7 protein disrupts normal SAGA and SLIK histone acetyltransferase activity. Proc. Natl. Acad. Sci. USA 102:8478-82
178. Meunier C, Bordereaux D, Porteu F, Gisselbrecht S, Chretien S, Courtois G. 2002. Cloning and characterization of a family of proteins associated with Mp1. J. Biol. Chem. 277:9139-47
179. n expansions associated with myotonic dystrophy. EMBO J. 19:4439-48
180. Miller WJ, Skinner JA, Foss GS, Davies KE. 2000. Localization of the fragile X mental retardation 2 (FMR2) protein in mammalian brain. Eur. J. Neurosci. 12:381-84
181. Minamiyama M, Katsuno M, Adachi H, Waza M, Sang C, et al. 2004. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 13:1183-92
182. Mineur YS, Sluyter F, de Wit S, Oostra BA, Crusio WE. 2002. Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. Hippocampus 12:39-46
183. Mizutani A, Wang L, Rajan H, Vig PJ, Alaynick WA, et al. 2005. Boat, an AXH domain protein, suppresses the cytotoxicity of mutant ataxin-1. EMBO J. 24:3339-51
184. Morfini G, Pigino G, Szebenyi G, You YM, Pollema S, Brady ST. 2006. JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat. Neurosci. 9:907-16
185. Moseley ML, Zu T, Ikeda Y, Gao WC, Mosemiller AK, et al. 2006. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat. Genet. 38:758-69
186. Moxley RT III, Griggs RC, Goldblatt D, VanGelder V, Herr BE, Thiel R. 1978. Decreased insulin sensitivity of forearm muscle in myotonic dystrophy. J. Clin. Invest. 62:857-67
187. Muhlenhoff U, Richhardt N, Ristow M, Kispal G, Lill R. 2002. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum. Mol. Genet. 11:2025-36
188. Mulley JC, Yu S, Loesch DZ, Hay DA, Donnelly A, et al. 1995. FRAXE and mental retardation. J. Med. Genet. 32:162-69
189. Muratani M, Tansey WP. 2003. How the ubiquitin-proteasome system controls transcription. Nat. Rev. Mol. Cell. Biol. 4:192-201
190. Mutsuddi M, Marshall CM, Benzow KA, Koob MD, Rebay I. 2004. The spinocerebellar ataxia 8 noncoding RNA causes neurodegeneration and associates with staufen in Drosophila. Curr. Biol. 14:302-8
191. Nakamura K, Jeong SY, Uchihara T, Anno M, Nagashima K, et al. 2001. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum. Mol. Genet. 10:1441-48
192. Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, et al. 1995. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811-23
193. Nemes JP, Benzow KA, Moseley ML, Ranum LP, Koob MD. 2000. The SCA8 transcript is an antisense RNA to a brain-specific transcript encoding a novel actin-binding protein (KLHL1). Hum. Mol. Genet. 9:1543-51
194. Neophytou C, Vernallis AB, Smith A, Raff MC. 1997. Muller-cell-derived leukaemia inhibitory factor arrests rod photoreceptor differentiation at a postmitotic pre-rod stage of development. Development 124:2345-54
195. Neuwald AF, Koonin EV. 1998. Ataxin-2, global regulators of bacterial gene expression, and spliceosomal snRNP proteins share a conserved domain. J. Mol. Med. 76:3-5
196. Nicastro G, Menon RP, Masino L, Knowles PP, McDonald NQ, Pastore A. 2005. The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. Proc. Natl. Acad. Sci. USA 102:10493-98
197. Nilson I, Reichel M, Ennas MG, Greim R, Knorr C, et al. 1997. Exon/intron structure of the human AF-4 gene, a member of the AF-4/LAF-4/FMR-2 gene family coding for a nuclear protein with structural alterations in acute leukaemia. Br. J. Haematol. 98:157-69
198. Nosyreva ED, Huber KM. 2006. Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J. Neurophysiol. 95:3291-95
199. Nucifora FCJ, Ellerby LM, Wellington CL, Wood JD, Herring WJ, et al. 2003. Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. J. Biol. Chem. 278:13047-55
200. Nucifora FCJ, Sasaki M, Peters MF, Huang H, Cooper JK, et al. 2001. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291:2423-28
201. Okazawa H, Rich T, Chang A, Lin X, Waragai M, et al. 2002. Interaction between mutant ataxin-1 and PQBP-1 affects transcription and cell death. Neuron 34:701-13
202. Orr HT. 2001. Beyond the Qs in the polyglutamine diseases. Genes Dev. 15:925-32
203. Orr HT, Chung MY, Banfi S, Kwiatkowski TJ Jr, Servadio A, et al. 1993. Expansion of an unstable trinucleotide (CAG) repeat in spinocerebellar ataxia type 1. Nat. Genet. 4:221-26
204. Palhan VB, Chen S, Peng GH, Tjernberg A, Gamper AM, et al. 2005. Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proc. Natl. Acad. Sci. USA 102:8472-77
205. Pan L, Zhang YQ, Woodruff E, Broadie K. 2004. The Drosophila fragile X gene negatively regulates neuronal elaboration and synaptic differentiation. Curr. Biol. 14:1863-70
206. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, et al. 2002. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 5:731-36
207. Paradee W, Melikian HE, Rasmussen DL, Kenneson A, Conn PJ, Warren ST. 1999. Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience 94:185-92
208. Park S, Gakh O, O'Neill HA, Mangravita A, Nichol H, et al. 2003. Yeast frataxin sequentially chaperones and stores iron by coupling protein assembly with iron oxidation. J. Biol. Chem. 278:31340-51
209. Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R, Nelson DL. 2000. (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum. Mol. Genet. 9:1145-59
210. Pietrobon D. 2002. Calcium channels and channelopathies of the central nervous system. Mol. Neurobiol. 25:31-50
211. Potter NT, Meyer MA, Zimmerman AW, Eisenstadt ML, Anderson IJ. 1995. Molecular and clinical findings in a family with dentatorubral-pallidoluysian atrophy. Ann. Neurol. 37:273-77
212. Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, et al. 2001. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 27:181-86
213. Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, et al. 1996. Identification of the SCA2 gene: moderate expansion of a normally biallelic trinucleotide repeat. Nat. Genet. 14:269-76
214. Qin M, Kang J, Burlin TV, Jiang C, Smith CB. 2005. Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. J. Neurosci. 25:5087-95
215. Ralser M, Albrecht M, Nonhoff U, Lengauer T, Lehrach H, Krobitsch S. 2005. An integrative approach to gain insights into the cellular function of human ataxin-2. J. Mol. Biol. 346:203-14
216. Ranum LP, Cooper TA. 2006. RNA-mediated neuromuscular disorders. Annu. Rev. Neurosci. 29:259-77
217. Ranum LP, Day JW. 2004. Pathogenic RNA repeats: an expanding role in genetic disease. Trends Genet. 20:506-12
218. Reddy S, Smith DB, Rich MM, Leferovich JM, Reilly P, et al. 1996. Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy. Nat. Genet. 13:325-35
219. Richards BW, Sylvester PE, Brooker C. 1981. Fragile X-linked mental retardation: the Martin-Bell syndrome. J. Ment. Defic. Res. 25(Pt. 4):253-56
220. Richardson DR, Mouralian C, Ponka P, Becker E. 2001. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim. Biophys. Acta 1536:133-40
221. Riess O, Schols L, Bottger H, Nolte D, Vieira-Saecker AM, et al. 1997. SCA6 is caused by moderate CAG expansion in the alpha1A-voltage-dependent calcium channel gene. Hum. Mol. Genet. 6:1289-93
222. Riley BE, Zoghbi HY, Orr HT. 2005. SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear localization signal. J. Biol. Chem. 280:21942-48
223. Rolfs A, Koeppen AH, Bauer I, Bauer P, Buhlmann S, et al. 2003. Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). Ann. Neurol. 54:367-75
224. Ross CA, Poirier MA. 2004. Protein aggregation and neurodegenerative disease. Nat. Med. 10(Suppl.):S10-17
225. Rotig A, de Lonlay P, Chretien D, Foury F, Koenig M, et al. 1997. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet. 17:215-17
226. Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, Sidi D, Munnich A, Rotig A. 1999. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 354:477-79
227. Sarkar PS, Appukuttan B, Han J, Ito Y, Ai C, et al. 2000. Heterozygous loss of Six5 in mice is sufficient to cause ocular cataracts. Nat. Genet. 25:110-14
228. Sarsero JP, Li L, Wardan H, Sitte K, Williamson R, Ioannou PA. 2003. Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. J. Gene Med. 5:72-81
229. Satterfield TF, Jackson SM, Pallanck LJ. 2002. A Drosophila homolog of the polyglutamine disease gene SCA2 is a dosage-sensitive regulator of actin filament formation. Genetics 162:1687-702
230. Satterfield TF, Pallanck LJ. 2006. Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes. Hum. Mol. Genet. 15:2523-32
231. Saudou F, Finkbeiner S, Devys D, Greenberg ME. 1998. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66
232. Savkur RS, Philips AV, Cooper TA. 2001. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat. Genet. 29:40-47
233. Savkur RS, Philips AV, Cooper TA, Dalton JC, Moseley ML, et al. 2004. Insulin receptor splicing alteration in myotonic dystrophy type 2. Am. J. Hum. Genet. 74:1309-13
234. Schaeffer C, Bardoni B, Mandel JL, Ehresmann B, Ehresmann C, Moine H. 2001. The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif. EMBO J. 20:4803-13
235. Scheel H, Tomiuk S, Hofmann K. 2003. Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics. Hum. Mol. Genet. 12:2845-52
236. Schmidt BJ, Greenberg CR, Allingham-Hawkins DJ, Spriggs EL. 2002. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 59:770-72
237. Seeler JS, Dejean A. 2003. Nuclear and unclear functions of SUMO. Nat. Rev. Mol. Cell. Biol. 4:690-99
238. Seilhean D, Takahashi J, El Hachimi KH, Fujigasaki H, Lebre AS, et al. 2004. Amyotrophic lateral sclerosis with neuronal intranuclear protein inclusions. Acta Neuropathol. 108:81-87
239. Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, et al. 2005. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet. 14:2871-80
240. Serra HG, Byam CE, Lande JD, Tousey SK, Zoghbi HY, Orr HT. 2004. Gene profiling links SCA1 pathophysiology to glutamate signaling in Purkinje cells of transgenic mice. Hum. Mol. Genet. 13:2535-43
241. Serra HG, Duvick L, Zu T, Carlson K, Stevens S, et al. 2006. RORα-mediated Purkinje cell development determines disease severity in adult SCA1 mice. Cell 127:697-708
242. Servadio A, Koshy B, Armstrong D, Antalfy B, Orr HT, Zoghbi HY. 1995. Expression analysis of the ataxin-1 protein in tissues from normal and spinocerebellar ataxia type 1 individuals. Nat. Genet. 10:94-98
243. Seznec H, Agbulut O, Sergeant N, Savouret C, Ghestem A, et al. 2001. Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities. Hum. Mol. Genet. 10:2717-26
244. Seznec H, Simon D, Bouton C, Reutenauer L, Hertzog A, et al. 2005. Friedreich ataxia: the oxidative stress paradox. Hum. Mol. Genet. 14:463-74
245. Sharp AH, Loev SJ, Schilling G, Li SH, Bao J, et al. 1995. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 14:1065-74
246. Shibata H, Huynh DP, Pulst SM. 2000. A novel protein with RNA-binding motifs interacts with ataxin-2. Hum. Mol. Genet. 9:1303-13
247. Siomi H, Siomi MC, Nussbaum RL, Dreyfuss G. 1993. The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 74:291-98
248. Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, et al. 2005. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl. Acad. Sci. USA 102:11402-7
249. Sobue G, Hashizume Y, Mukai E, Hirayama M, Mitsuma T, Takahashi A. 1989. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112:209-32
250. Spencer CM, Serysheva E, Yuva-Paylor LA, Oostra BA, Nelson DL, Paylor R. 2006. Exaggerated behavioral phenotypes in Fmr1/Fxr2 double knockout mice reveal a functional genetic interaction between fragile X-related proteins. Hum. Mol. Genet. 15:1984-94
251. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, et al. 2001. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739-43
252. Stowers RS, Megeath LJ, Gorska-Andrzejak J, Meinertzhagen IA, Schwarz TL. 2002. Axonal transport of mitochondria to synapses depends on milton, a novel Drosophila protein. Neuron 36:1063-77
253. Stromme P, Mangelsdorf ME, Shaw MA, Lower KM, Lewis SM, et al. 2002. Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy. Nat. Genet. 30:441-45
254. Strong TV, Tagle DA, Valdes JM, Elmer LW, Boehm K, et al. 1993. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat. Genet. 5:259-65
255. Su MA, Wisotzkey RG, Newfeld SJ. 2001. A screen for modifiers of decapentaplegic mutant phenotypes identifies lilliputian, the only member of the Fragile-X/Burkitt's Lymphoma family of transcription factors in Drosophila melanogaster. Genetics 157:717-25
256. Sutherland GR. 1977. Fragile sites on human chromosomes: demonstration of their dependence on the type of tissue culture medium. Science 197:265-66
257. Szebenyi G, Morfini GA, Babcock A, Gould M, Selkoe K, et al. 2003. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40:41-52
258. Tait D, Riccio M, Sittler A, Scherzinger E, Santi S, et al. 1998. Ataxin-3 is transported into the nucleus and associates with the nuclear matrix. Hum. Mol. Genet. 7:991-97
259. Takahashi J, Tanaka J, Arai K, Funata N, Hattori T, et al. 2001. Recruitment of nonexpanded polyglutamine proteins to intranuclear aggregates in neuronal intranuclear hyaline inclusion disease. J. Neuropathol. Exp. Neurol. 60:369-76
260. Takano H, Gusella JF. 2002. The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB/Rel/dorsal family transcription factor. BMC Neurosci. 3:15
261. Takeyama K, Ito S, Yamamoto A, Tanimoto H, Furutani T, et al. 2002. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35:855-64
262. Tamanini F, Meijer N, Verheij C, Sillems P, Galjaard H, et al. 1996. FMRP is associated to the ribosomes via RNA. Hum. Mol. Genet. 5:809-13
263. 2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc. Natl. Acad. Sci. USA 102:2602-7
264. Tassone F, Hagerman RJ, Garcia-Arocena D, Khandjian EW, Greco CM, Hagerman PJ. 2004. Intranuclear inclusions in neural cells with premutation alleles in fragile X associated tremor/ataxia syndrome. J. Med. Genet. 41:e43
265. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. 2000. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am. J. Hum. Genet. 66:6-15
266. Thierbach R, Schulz TJ, Isken F, Voigt A, Mietzner B, et al. 2005. Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice. Hum. Mol. Genet. 14:3857-64
267. n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res. 24:4407-14
268. Todd PK, Mack KJ, Maker JS. 2003. The fragile X mental retardation protein is required for type-I metabotropic glutamate receptor-dependent translation of PSD-95. Proc. Natl. Acad. Sci. USA 100:14374-78
269. Tsai CC, Kao HY, Mitzutani A, Banayo E, Rajan H, et al. 2004. Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc. Natl. Acad. Sci. USA 101:4047-52
270. Tsuda H, Jafar-Nejad H, Patel AJ, Sun Y, Chen HK, et al. 2005. The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins. Cell 122:633-44
271. Turner G, Webb T, Wake S, Robinson H. 1996. Prevalence of fragile X syndrome. Am. J. Med. Genet. 64:196-97
272. Uchihara T, Fujigasaki H, Koyano S, Nakamura A, Yagishita S, Iwabuchi K. 2001. Non-expanded polyglutamine proteins in intranuclear inclusions of hereditary ataxias - triple-labeling immunofluorescence study. Acta Neuropathol. 102:149-52
273. Utsch B, Becker K, Brock D, Lentze MJ, Bidlingmaier F, Ludwig M. 2002. A novel stable polyalanine [poly(A)] expansion in the HOXA13 gene associated with hand-foot-genital syndrome: Proper function of poly(A)-harbouring transcription factors depends on a critical repeat length? Hum. Genet. 110:488-94
274. Uyama E, Kondo I, Uchino M, Fukushima T, Murayama N, et al. 1995. Dentatorubral-pallidoluysian atrophy (DRPLA): clinical, genetic, and neuroradiologic studies in a family. J. Neurol. Sci. 130:146-53
275. Ventura R, Pascucci T, Catania MV, Musumeci SA, Puglisi-Allegra S. 2004. Object recognition impairment in Fmr1 knockout mice is reversed by amphetamine: involvement of dopamine in the medial prefrontal cortex. Behav. Pharmacol. 15:433-42
276. Verkerk AJMH, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DPA, et al. 1991. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65:905-14
277. Vihola A, Bassez G, Meola G, Zhang S, Haapasalo H, et al. 2003. Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology 60:1854-57
278. Vonsattel JP, DiFiglia M. 1998. Huntington disease. J. Neuropathol. Exp. Neurol. 57:369-84
279. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EPJ. 1985. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44:559
280. Wakamiya M, Matsuura T, Liu Y, Schuster GC, Gao R, et al. 2006. The role of ataxin 10 in the pathogenesis of spinocerebellar ataxia type 10. Neurology 67:607-13
281. 2+ channels: rle in channel function. Trends Neurosci. 21:148-54
282. Warren ST, Sherman SL. 2001. The fragile X syndrome. In Metabolic Basis of Inherited Disease, ed. CR Scriver, AL Beaudet, WS Sly, D Valle, pp. 1257-90. New York: McGraw-Hill
283. Warrick JM, Morabito LM, Bilen J, Gordesky-Gold B, Faust LZ, et al. 2005. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol. Cell. 18:37-48
284. Weiler IJ, Spangler CC, Klintsova AY, Grossman AW, Kim SH, et al. 2004. Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses. Proc. Natl. Acad. Sci. USA 101:17504-9
285. Wessel K, Schroth G, Diener HC, Muller-Forell W, Dichgans J. 1989. Significance of MRI-confirmed atrophy of the cranial spinal cord in Friedreich's ataxia. Eur. Arch. Psychiatry Neurol. Sci. 238:225-30
286. Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, et al. 2006. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1α in Huntington's disease neurodegeneration. Cell Metab. 4:349-62
287. Wheeler VC, Gutekunst CA, Vrbanac V, Lebel LA, Schilling G, et al. 2002. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum. Mol. Genet. 11:633-40
288. Wiedemeyer R, Westermann F, Wittke I, Nowock J, Schwab M. 2003. Ataxin-2 promotes apoptosis of human neuroblastoma cells. Oncogene 22:401-11
289. Wittwer F, van der Straten A, Keleman K, Dickson BJ, Hafen E. 2001. Lilliputian: an AF4/FMR2-related protein that controls cell identity and cell growth. Development 128:791-800
290. Wong A, Yang J, Cavadini P, Gellera C, Lonnerdal B, et al. 1999. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet. 8:425-30
291. Xu K, Bogert BA, Li W, Su K, Lee A, Gao FB. 2004. The fragile X-related gene affects the crawling behavior of Drosophila larvae by regulating the mRNA level of the DEG/ENaC protein pickpocket1. Curr. Biol. 14:1025-34
292. Yamamoto A, Lucas JJ, Hen R. 2000. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101:57-66
293. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. 2005. Suppression of two major fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49:1053-66
294. Yoo SY, Pennesi ME, Weeber EJ, Xu B, Atkinson R, et al. 2003. SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron 37:383-401
295. Yoon T, Cowan JA. 2003. Iron-sulfur cluster biosynthesis. Characterization of frataxin as an iron donor for assembly of [2Fe-2S] clusters in ISU-type proteins. J. Am. Chem. Soc. 125:6078-84
296. Yue S, Serra HG, Zoghbi HY, Orr HT. 2001. The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract. Hum. Mol. Genet. 10:25-30
297. Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A. 1995. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 11:155-63
298. Zhai W, Jeong H, Cui L, Krainc D, Tjian R. 2005. In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 123:1241-53
299. Zhang J, Gray J, Wu L, Leone G, Rowan S, et al. 2004. Rb regulates proliferation and rod photoreceptor development in the mouse retina. Nat. Genet. 36:351-60
300. Zhang S, Xu L, Lee J, Xu T. 2002. Drosophila atrophin homolog functions as a transcriptional corepressor in multiple developmental processes. Cell 108:45-56
301. Zhang Y, O'Connor JP, Siomi MC, Srinivasan S, Dutra A, et al. 1995. The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and. EMBO J. 14:5358-66
302. Zhou ZX, Wong CI, Sar M, Wilson EM. 1994. The androgen receptor: an overview. Recent Prog. Horm. Res. 49:249-74
303. 1A-voltage-dependent calcium channel. Nat. Genet. 15:62-69
304. Zoghbi HY, Orr HT. 2000. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23:217-47
305. Zu T, Duvick LA, Kaytor MD, Berlinger MS, Zoghbi HY, et al. 2004. Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. 24:8853-61
306. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, et al. 2001. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293:493-98
307. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, et al. 2003. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35:76-83